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Abstract
B cell-activating factor (BAFF) is a cytokine belonging to the tumor necrosis factor (TNF) superfamily. It has been reported
that BAFF is elevated in patients with autoimmune pancreatitis and contributes to the malignant potential of blood cancers
and solid tumors. In this study, clinical evidence of increased BAFF levels in patients with pancreatic ductal adenocarcinoma
(PDAC) was obtained, and the roles and mechanisms of BAFF in PDAC were clarified in human tissues of PDAC and from in
vitro data of PDAC cell lines. Serum levels of BAFF in patients with PDAC were significantly higher than in healthy subjects
(p = 0.0121). Patients with UICC stage IV PDAC (T1-4, N0-1, M1) had significantly higher levels of serum BAFF compared to
patients with PDAC (p = 0.0182). BAFF was remarkably expressed in infiltrating B lymphocytes surrounding pancreatic
cancer in human pancreatic tissues, suggesting that BAFF may play a role in progression of pancreatic cancer. PDAC cell
lines were cultured with human recombinant BAFF, and morphology and gene expression were analyzed; pancreatic cancer
cells changed to a fibroblast-like morphology, and showed altered gene expression of E-cadherin, vimentin and Snail. These
BAFF-induced changes reflect enhanced cell motility and invasion. BAFF-R-overexpressing cell clones confirmed the
association between these BAFF-induced changes and epithelial-mesenchymal transition (EMT)-related genes. BAFF was
elevated in patients with metastatic advanced PDAC and induced alterations in PDAC cells via regulation of EMT-related
genes. Elucidation of the precise role and mechanism of control of BAFF may lead to new therapeutic approaches with the
aim of improving pancreatic cancer survival.
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Introduction
Pancreatic cancer is one of the cancers with the poorest
prognosis in humans. The 5-year survival rate of pancreatic cancer
is only about 6% due to the difficulty in diagnosis in early clinical
stages, as well as to frequent metastases [1,2]. Recently, new
therapeutic options have been reported; however, treatment
options are limited and the response to chemotherapy remains
low [3,4]. Identification of novel targets for pancreatic cancer
could improve prognosis.
It has recently been reported that B cell-activating factor
(BAFF), a proinflammatory cytokine, is elevated in patients with
autoimmune pancreatitis [5]. BAFF is a cytokine that belongs to a
subset of the tumor necrosis factor (TNF) superfamily. In a
previous experiment in which serum levels of BAFF were
examined in patients with pancreatic cancer [5], patients with
metastasis appeared to have increased levels of BAFF.
BAFF is a 285-amino acid peptide glycoprotein that is expressed
as a transmembrane protein, and is secreted in a soluble form from
various cell types (monocytes, dendritic cells, T lymphocytes, and
B lymphocytes) [6–8]. It is known to be associated with survival
and maturation of B lymphocytes. BAFF is a ligand for three
receptors: BAFF-receptor (BAFF-R) [9]; transmembrane activator,
calcium-modulator, and cyclophilin ligand interactor (TACI) [10];
and B cell maturation antigen (BCMA) [11]. Moreover, a protein
similar to BAFF, named a proliferation-inducing ligand (APRIL)
[12], may be a ligand of TACI and BCMA. Binding of BAFF or
APRIL to those receptors can activate various signaling pathways,
including the nuclear factor-kB (NF-kB) pathway [13–15]. It has
been reported that BAFF and APRIL contribute to the malignant
potential of blood cancers and solid tumors [16–18]. However, the
roles of BAFF, APRIL, and their receptors in pancreatic cancer
have not yet been elucidated.
In this study, clinical evidence of increased BAFF levels in
patients with pancreatic ductal adenocarcinoma (PDAC) was
obtained, and the role and mechanism of BAFF in PDAC was
clarified from clinical evidence and from in vitro data from PDAC
cell lines.
Materials and Methods
Patients and pancreas specimens
Serum samples were examined from 44 patients with PDAC
and healthy age- and sex-matched subjects. For diagnosis of
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staging, the tumor node metastasis system of the Union for
International Cancer Control (UICC) was used. All serum samples
were stored at 280uC before use. Specimens of PDAC were
obtained from patients who underwent surgery. Written informed
consent was obtained from all enrolled participants. The study
protocol conformed to the ethical guidelines of the 1975
Declaration of Helsinki, and was approved by the Institutional
Review Board of Ehime University Hospital (Approval number:
1107003). This study involving human specimens was registered in
the University Hospital Medical Information Network (UMIN)
Clinical Trials Registry (registration number 000008654).
Enzyme-linked immunosorbent assay for BAFF and APRIL
Serum levels of BAFF and APRIL in all subjects were assayed
using an enzyme-linked immunosorbent assay kit (R&D Systems,
Minneapolis, MN, USA for BAFF; BioVendor, Candler, NC,
USA for APRIL) following the manufacturer’s recommendations.
Immunohistochemistry of PDAC specimens
Pancreatic tissues were fixed in formalin. Sections (3 mm thick)
were cut from each block and adjacent sections were stained with
standard hematoxylin and eosin (H&E) and immunohistochemical
staining techniques. Paraffin-embedded samples were dewaxed
and rehydrated, and then antigens were retrieved by autoclaving
for 1 min at 125uC in EDTA buffer (pH 9.0). Endogenous
peroxidase activity was inactivated by incubation with methanol
containing 1% hydrogen peroxidase for 20 min. The sections were
then incubated in 1% blocking serum for 30 min to reduce
nonspecific reactions. For immunohistochemistry, the sections
were incubated with the relevant primary antibody (Table S1) at
4uC overnight. The tissue sections were treated with peroxidase-
Figure 1. Serum levels of BAFF and APRIL in patients with PDAC. (A) Serum levels of BAFF were determined in patients with PDAC (n = 44)
and in healthy subjects (n = 44). (B) Serum levels of APRIL were determined in patients with PDAC (n= 44) and in healthy subjects (n = 44). (C) Serum
levels of BAFF and UICC stage of PDAC are indicated. (D) Serum levels of BAFF and tumor sizes of primary PDAC were significantly correlated in 44
patients (p,0.001). Data are shown as means 6 SD (*p,0.05). n.s.; not significant.
doi:10.1371/journal.pone.0071367.g001
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labeled secondary antibody (Histofine Simplestain Max PO;
Nichirei, Tokyo, Japan) for 1 h at room temperature, and
incubated with Simple Stain DAB Solution (Nichirei). Photomi-
crographs were taken using a Nikon Microphot FXA with a Nikon
Digital Camera DXM 1200 (Nikon, Tokyo, Japan).
For the immunofluorescence staining, mounted and formalin-
fixed sections were used. Sections were incubated with the relevant
primary antibody (Table S1) at 4uC overnight. After washing with
phosphate-buffered saline, the sections were incubated with
DyLight488-conjugated donkey anti-goat antibody for BAFF or
BAFF-R, and with DyLight549-conjugated donkey anti-mouse
antibody for CD20. The nuclei of the sections were stained with
4,6-diamidino-2-phenylindole (Wako, Osaka, Japan). Slides were
imaged using a Zeiss Axioskop 2 Plus fluorescence microscope and
captured by a Zeiss AxioCam HRc digital camera (Zeiss, Tokyo,
Japan) and saved to a computer. The photographs stained for
BAFF, BAFF-R and CD20 were merged to evaluate their locations
in the cells.
Cells and culture conditions
Four pancreatic cancer cell lines (PANC-1, BxPC-3, AsPC-1
and MIA PaCa-2 cells), which were initially generated from
patients with PDAC, and Ramos cells were obtained from the
American Type Culture Collection (ATCC, Manassas, VA, USA).
The PANC-1 and MIA PaCa-2 cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM; Life Technologies, Carlsbad,
CA, USA) supplemented with 10% fetal bovine serum (Life
Technologies) and 1% penicillin. BxPC-3, AsPC-1 and Ramos
cells were cultured in RPMI-1640 supplemented with 10% fetal
bovine serum and 1% penicillin. Microphotographs were obtained
after various treatments on an inverted microscope (Olympus
IX70, Olympus, Tokyo, Japan) equipped with an Olympus DP12
digital camera. After being serum starved for 24 h, cells were
incubated with recombinant BAFF (Reliatech, Braunschweig,
Germany) and recombinant TGF-b (R&D Systems) for 48 h. For
neutralizing the BAFF, goat anti-BAFF-R antibody (R&D
Systems) was used, and goat IgG antibody (R&D Systems) was
used as a control antibody.
RNA extraction, cDNA synthesis and real-time RT-PCR
The RNA was reverse transcribed using RT-PCR kits (Applied
Biosystems, Foster City, CA, USA) with an oligo d(T)16 primer
under standard conditions. Real-time PCR amplification was
performed using a LightCycler 480 (Roche, Basel, Switzerland)
and 2 mL of purified cDNA product, 0.5 mL of sense primer
(10 pmol/ mL), 0.5 mL of antisense primer (10 pmol/ ml), 1 mL of
Table 1. Clinical background of patients with pancreatic
cancer and healthy subjects.
Healthy subjects
(n =44) PDAC (n=44) p-value
Age (years) 67 (40–92) 68 (40–89) 0.970
Gender (M/F) 26/18 26/18 1.000
BAFF (pg/mL) 1147 6 315 1704 6 1409 0.0121
APRIL (ng/mL) 7.3 6 2.2 7.7 6 2.4 0.895
Data are presented as numbers or means 6 SD. PDAC, pancreatic ductal
adenocarcinoma; BAFF, B cell-activating factor; APRIL, a proliferation-inducing
ligand.
doi:10.1371/journal.pone.0071367.t001
Table 2. Clinical background of patients with pancreatic ductal adenocarcinoma.
UICC stage Total (n = 44) Ib-III (n =18) IV (n =26) p-value
Age (years) 67.9 6 11.6 67.1 6 12.7 68.5 6 11.4 0.713
Gender (M/F) 26/18 12/6 14/12 0.395
Location 0.050
Head 24 13 11
Body and tail 20 5 15
Tumor Size (mm) 35.5 6 13.9 26.9 6 9.9 41.5 6 13.3 ,0.001
Primary tumor (T) 0.001
T2 3 3 0
T3 15 10 5
T4 26 5 21
Regional lymph nodes (N) 0.911
N0 20 8 12
N1 24 10 14
Distant metastasis (M) ,0.001
M0 18 18 0
M1 26 0 26
CEA (ng/m) 28.2 6 83.7 5.0 6 4.9 44.3 6 106.6 0.0725
CA19-9 (U/mL) 9009 6 40996 777 6 1734 14709 6 52974 0.192
BAFF (pg/mL) 1704 6 1409 1186 6 328 2063 6 1736 0.0182
APRIL (ng/mL) 7.7 6 2.4 3.9 6 3.6 10.3 6 18.9 0.0998
Data are presented as number or mean 6 SD. UICC, International Union Against Cancer; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; BAFF, B
cell-activating factor; APRIL, a proliferation-inducing ligand.
doi:10.1371/journal.pone.0071367.t002
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LightCycler Fast Start DNA Master SYBR Green I (Roche), and
0.8 mL of MgCl2 (25 mmol/L) (experimental conditions and
sequences of the primers used to amplify human genes are
indicated in Table S2). Commercial glyceraldehyde phosphate
dehydrogenase (GAPDH) primer sets and b-actin primer sets
(Roche) were used for PCR amplification under the conditions
recommended by the manufacturer. GAPDH served as an internal
reference gene, and the relative change was calculated by relative
quantification, applying the formula 22DDCt. Reaction products
were separated on 2% agarose gels.
Western blotting
For Western blotting, 20 mg of protein was applied to the lanes
of 4% to 12% Bis-Tris Gels (Life Technologies), then blotted onto
Immobilon-P membranes (Millipore, Bedford, MA, USA), and
incubated with the relevant primary antibody (Table S1).
Appropriate species-specific conjugated secondary antibody kits
were commercially obtained (GE Healthcare, Tokyo, Japan).
Proteins were detected using the ECL prime Kit or the ECL Kit
(GE Healthcare) with an ImageQuant LAS 4000 system (GE
Healthcare).
Wound healing/scratch test
PANC-1 cells were seeded into 6-well plates and incubated for
24 h under a serum-starved condition. After confirming that a
complete monolayer had formed, the monolayers were wounded
by scratching lines with a plastic tip. The wells were then washed
once to remove any debris, and observed and photographed under
the microscope. Thereafter, the plates were incubated at 37uC
under 5% CO2 for 24 h with the recombinant human BAFF
(Reliatech), after which the cells were observed and photographed.
Cells were visualized with an Olympus Model IX70 inverted
microscope (Olympus) using a 46objective. Images were captured
with an Olympus DP12 a digital camera (Olympus). The distance
that the cells had migrated was measured on the photomicro-
graphs. The percent wounded area filled was calculated as follows:
{(mean wounded breadth – mean remained breadth)/mean
wounded breadth}6 100 (%) [19].
Invasion assay
To investigate cell invasion, a 96-well cell invasion assay kit
(Cultrex, Trevigen, Gaithersburg, MD, USA) was used according
to the manufacturer’s instructions.
Establishment of human BAFF-R transfectant cell clones
Cell clones overexpressing BAFF-R were developed using a
plasmid, which could express the BAFF-R gene and the G418-
resistant gene (pBCMGS-BAFF-R) [20]. PANC-1 cells were
transfected with pBCMGS-BAFF-R using Lipofectamin 2000
(Life Technologies), and the transfected cell clones were selected
by incubation with G418 (1000 mg/mL, Life Technologies).
Finally, four cell clones that over-expressed BAFF-R were
established.
Flow cytometric analysis
Flow cytometric analysis was performed for the stained PANC-1
cells and human BAFF-R transfected cell clones. BAFF-R was
detected with primary antibody specific for the BAFF-R (Table S1)
followed by an additional incubation with Alexa 488-conjugated
secondary antibody for goat IgG (Abcam, Tokyo, Japan). Those
stained cells were examined using a FACScalibur (Becton
Dickinson, Franklin Lakes, NJ, USA) and analyzed with FlowJo
software (TreeStar Corporation, Ashland, OR, USA).
Statistical analysis
All statistical analyses were performed using JMP 8.0 (SAS
Institute, Tokyo, Japan). Data expressed are means and standard
error (SE) or means and standard deviation (SD). Differences were
analyzed using the Student t-test, Wilcoxon test and x2 test.
Statistical significance was defined as p,0.05 based on a two-
tailed test. Correlations between two variables were evaluated by
using Pearson’s coefficient of correlation, and p-values of ,0.05
were considered to represent statistical significance.
Results
Serum levels of BAFF in patients with advanced PDAC
Serum levels of BAFF and APRIL were examined in patients
with PDAC and in healthy age- and sex-matched subjects
(Table 1). Serum levels of BAFF were 1704 6 1409 pg/mL
(mean 6 SD) in patients with PDAC, significantly higher than in
healthy subjects (1147 6 315 pg/mL; p= 0.0121) (Fig. 1A). On
the other hand, serum levels of APRIL in patients with PDAC
were not significantly higher than in healthy subjects (7.7 6 2.4 vs.
Figure 2. Immunohistochemistry of BAFF and BAFF receptor in
human PDAC tissue. (A) Staining with hematoxylin and eosin (H&E)
and immunohistochemistry of BAFF, BAFF-R, CD3, CD20 and CD68 in
PDAC and surrounding tissues are shown. First Ab (-) indicates staining
control without first antibody. The B lymphocytes in the tissue
surrounding PDAC had a remarkably high level of BAFF expression.
Magnification as indicated above each photomicrograph. Scale bars
represent 200 mm under low magnification (x40), and 50 mm under high
magnification (x200 and6400).
doi:10.1371/journal.pone.0071367.g002
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7.3 6 2.2 pg/mL, respectively; p = 0.895) (Fig. 1B). The increase
in serum levels of BAFF was evaluated by UICC stage. Patients
with UICC stage IV PDAC (T1-4, N0-1, M1) had significantly
higher levels of serum BAFF than the patients with UICC stage Ib-
III (20636 1736 vs. 1186 6 328 pg/mL, respectively; p= 0.0182)
(Fig. 1C). The clinical background of the patients at each stage is
indicated in Table 2. Concerning the relationship between the
serum levels of BAFF and PDAC tumor size, there was a
significant positive correlation, as indicated in Fig. 1D (r = 0.348;
p,0.001). This suggested that the increase in serum levels of
BAFF was associated with tumor growth and metastasis of PDAC.
Expression of BAFF and BAFF-R in human PDAC tissue
Immunohistochemistry experiments were performed to deter-
mine whether BAFF is expressed in pancreatic tissue. Pancreatic
tissue from surgical species obtained from patients with PDAC was
stained for BAFF and BAFF-R (Fig. 2 and 3). Tumor-infiltrating
immune cells surrounding PDAC cells were found to remarkably
express BAFF and BAFF-R (Fig. 2). Additional staining of CD20
Figure 3. Immunofluorescence of BAFF and BAFF receptor in human PDAC tissue. (A) Immunofluorescence staining with BAFF (green),
and CD20, CD3, CD68 (red) are shown. The merged image is indicated as ‘‘merge’’. Expressions of BAFF and CD20 were co-localized (yellow); however,
BAFF and CD3 or CD68 were not co-localized. (B) Immunofluorescence staining with BAFF-R (green) and CD20, CD3, and CD68 (red) are shown.
Expression of BAFF-R and CD20 were co-localized (yellow); however, BAFF-R and CD3 or CD68 were not co-localized. First Ab (-) indicates staining
control without the first antibody.
doi:10.1371/journal.pone.0071367.g003
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(a marker of B lymphocytes), CD3 (T cell receptor, a marker of T
lymphocytes) and CD68 (a marker of monocytes/macrophages)
was performed to identify their types of infiltrating cells expressing
BAFF or BAFF-R. The distribution of BAFF- and BAFF-R-
positive cells appeared consistent with the distribution of B
lymphocytes, rather than that of T lymphocytes or monocyte/
macrophages (Fig. 2). Recently, it has been shown that B
lymphocytes can secrete BAFF [7,8,16]. Double immunofluores-
cence staining with BAFF and CD20, CD3, CD68 (Fig. 3A), and
staining with BAFF-R and CD20, CD3, CD68 (Fig. 3B) was
performed. The distribution of BAFF (green) and CD20 (red) was
merged and appeared yellow (Fig. 3A). Moreover, the distribution
of BAFF-R (green) and CD20 (red) was also merged and appeared
yellow (Fig. 3B). However, the distribution of BAFF and BAFF-R
were not co-localized with CD3 or CD68. These results indicate
that B lymphocytes, which express high levels of BAFF and BAFF-
R, are in the infiltrate and proliferate in the tissue surrounding the
PDAC.
Expression of BAFF receptors in human PDAC tissues and
human PDAC cell lines
In order to investigate the expression of BAFF receptors in
PDAC, immunohistochemistry was performed on PDAC tissues
obtained from patients as well as on human PDAC cell lines.
BAFF-R was expressed in PDAC cells, which had positive signals
of MIB-1 and CA19-9 (Fig. 4A, left column). However, other
BAFF receptors (TACI and BCMA) were not expressed in the
PDAC cells (Fig. 4A, right column). The human PDAC cell lines,
PANC-1, BxPC-3, AsPC-1, and MIA PaCa-2, were used for the in
vitro studies. Qualitative RT-PCR for the gene expression of
BAFF-R, TACI, and BCMA revealed only expression of BAFF-R
(Fig. 4B). Ramos cells, known as a tissue that expresses BAFF-R,
TACI and BCMA, were used as a positive control [21]. Moreover,
Western blotting was performed to evaluate the protein expression
of these BAFF receptors (Fig. 4C). Expression of BAFF-R was
confirmed in all of the PDAC cell lines, but expression of TACI
and BCMA could not be detected. Taken together, these results
Figure 4. Expression of BAFF receptors in human PDAC tissue and human PDAC cell lines. (A) Staining with hematoxylin and eosin (H&E)
and immunohistochemistry of MIB-1, CA19-9, BAFF-R, TACI and BCMA in PDAC are shown. First Ab (-) indicates staining control without the first
antibody. Magnification is as indicated above each photomicrograph. Scale bars represent 200 mm under low magnification (x40), and 50 mm under
high magnification (x400). (B) Qualitative RT-PCR analysis of BAFF receptors in PDAC cell lines. GAPDH is indicated as a housekeeping gene. RNA
isolated from Ramos cell was used as a positive control. N.C. is a negative control without sample. (C) Western blot analysis of BAFF receptors in PDAC
cell lines. b-actin is indicated as a housekeeping protein. Ramos cell was used as a positive control. N.C. is a negative control without sample.
doi:10.1371/journal.pone.0071367.g004
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showed that increased levels of BAFF resulted from the infiltrating
and proliferating B lymphocytes surrounding PDAC tissues; these
increased levels of BAFF can stimulate PDAC through BAFF-R
signaling. To identify the role of BAFF in PDAC, an in vitro assay
was performed using the PANC-1 PDAC cell line, its cloned
transfectant of BAFF-R, and recombinant human BAFF for
further analysis.
BAFF induces EMT in a PDAC cell line
In the in vitro assay, the cell morphology of PANC-1 was
observed to change after addition of recombinant human BAFF to
the culture medium (Fig. 5A). The cells appeared to adopt a more
fibroblast-like (spindle type) morphology and showed reduced cell-
cell contact. These morphologic changes were similar to changes
seen with TGF-b treatment. From this result, it was hypothesized
that increased BAFF might induce alterations in genes related to
the epithelial-mesenchymal transition (EMT) in PDAC cells.
PANC-1 is isolated from undifferentiated PDAC tissue [22] and is
positive for the epithelial marker E-cadherin and the mesenchymal
protein vimentin. Thus, PANC-1 was used as a model of a PDAC
cell that still has an epithelial potential. Analysis for altered
expression of representative genes related to EMT was performed
by adding human recombinant BAFF to the culture medium. A
significant downregulation of E-cadherin mRNA, as well as
significant upregulation of vimentin and Snail mRNAs, were
observed in a dose-dependent manner with BAFF (Fig. 5B).
GAPDH mRNA was used as a housekeeping gene for the
quantitative PCR, and it was confirmed that the levels of GAPDH
mRNA were not altered by treatment with BAFF (Fig. S1).
Western blotting results for these molecules were similar to the
results of real-time RT-PCR (Fig. 5C). The BAFF-induced
alterations in PDAC cells were similar to alterations seen during
EMT. Increased BAFF in PDAC could promote gene alterations
Figure 5. BAFF induces changes associated with epithelial-mesenchymal transition (EMT) in a PDAC cell line. (A) The cellular
morphology of PANC-1 cells changed after the addition of BAFF to the supernatant. TGF-b was used as a positive control. Similar to TGF-b, addition of
BAFF caused the morphology of PANC-1 cells to become spindle-like. (B) Analysis of real-time RT-PCR for EMT markers (E-cadherin, vimentin, and
Snail) are indicated. These genes were modulated in a dose-dependent manner with BAFF. Data are shown as means 6 SE of four separate
experiments (*p,0.05 vs. BAFF 0 ng/mL). (C) Western blotting analysis of EMT markers indicates that the expression of each protein was modulated
by the addition of BAFF. b-actin is shown as a housekeeping protein.
doi:10.1371/journal.pone.0071367.g005
BAFF Promotes Tumor Invasion in Pancreatic Cancer
PLOS ONE | www.plosone.org 7 August 2013 | Volume 8 | Issue 8 | e71367
associated with EMT through a decrease in E-cadherin and an
increase in vimentin via the Snail signaling pathways.
Treatment with human recombinant BAFF and motility
and invasion of PDAC cells
In conjunction with morphologic changes, it was suggested that
BAFF induces EMT in PDAC. These results prompted study of
the other effects of BAFF, such as motility and invasion. PANC-1
cells were incubated with human recombinant BAFF, and changes
in motility were evaluated with the wound healing/scratch test.
Treatment with BAFF increased the motility of PANC-1 cells and
resulted in accelerated wound closure (p,0.01) (Fig. 6A and 6B).
Moreover, treatment with human recombinant BAFF significantly
improved the ability of cells to invade the extracellular matrix in
vitro (Fig. 6C).
Additional assays were performed using anti-human BAFF-R
antibody, which can inhibit the binding of BAFF to BAFF-R [23].
With addition of human recombinant BAFF to the supernatant of
the cultured cells, the percent wounded area filled increased
significantly (15.1 6 2.3 vs. 27.2 6 2.3; p,0.01). With addition of
both human recombinant BAFF and the anti-human BAFF-R
antibody, wound closure was diminished significantly compared to
the addition of control goat antibody (27.2 6 2.3 vs. 20.9 6 2.4;
p,0.05) (Fig. 6D and 6E). These data suggest that BAFF
stimulation caused increased motility and invasion of PANC-1
cells.
BAFF-R-overexpressing cell clones and expression of
EMT-related genes
Four cell clones that can overexpress BAFF-R through
transfection with a plasmid (pBCMGS-BAFF-R) [20] and selection
Figure 6. Treatment with human recombinant BAFF increases motility and invasion of PDAC cells. (A) The wound healing/scratch test
indicated that the motility of PANC-1 cells was enhanced by 24 h of incubation with BAFF. (B) The percent wounded area filled in the wound healing/
scratch test is shown as a graph (*p,0.01 vs. BAFF 0 ng/mL). (C) The invasion assay shows enhancement of invasion with BAFF in PANC-1 cells
(*p,0.05 vs. BAFF 0 ng/mL). (D) The wound healing/scratch test with neutralizing anti-BAFF-R antibody indicated that the motility of PANC-1 cells
with BAFF was inhibited by the antibody. (E) The percent wounded area filled in the wound healing/scratch test is shown as a graph. Data are shown
as means 6 SE of six separate experiments (*p,0.05, **p,0.01).
doi:10.1371/journal.pone.0071367.g006
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by culturing with G418 were established. Overexpression of
BAFF-R was confirmed in these cell clones by Western blotting
and FACS analysis (Fig. 7A and S2). Functional signaling of
transduced BAFF-R in these cell clones were confirmed by
incubating with BAFF (Fig. S3). Increased expression of NF-kB
p52 protein was seen on Western blotting, indicating that the NF-
kB pathway was activated by overexpression of BAFF-R; this
activation of the NF-kB pathway was also reflected in the
decreased expression of E-cadherin and increased expression of
vimentin and Snail in these clones. Those alterations were similar
to the results of the assay with recombinant human BAFF.
Moreover, expression of mRNAs was evaluated using real-time
RT-PCR (Fig. 7B). A decrease in E-cadherin mRNA was observed
in all of the BAFF-R-overexpressing cell clones, while an increase
in vimentin and Snail mRNAs was observed in most of the cell
clones. Motility of cell clones was confirmed to be significantly
higher than that of non-BAFF-R-transfected PANC-1 cells on the
wound healing/scratch test (Fig. 7C and D). Taken together with
the results from the cell clones, it was confirmed that stimulation
with BAFF induces gene alterations associated with EMT in
PDAC cells.
Discussion
This is the first study to report that serum levels of BAFF are
increased in patients with PDAC, and the first study to investigate
the role of BAFF in human PDAC. In this study, it was revealed
that: i) serum levels of BAFF in patients with PDAC (in particular,
in those with metastasis) were elevated compared to healthy
subjects; ii) tumor-infiltrating B lymphocytes expressed BAFF and
PDAC tissues expressed BAFF-R; and iii) increased BAFF-induced
gene alterations were associated with EMT in a PDAC cell line,
and with enhanced tumor cell motility and invasion.
BAFF is known to be expressed by monocytes, dendritic cells, T
lymphocytes, B lymphocytes, and epithelial cells [6–8,24,25];
however, its precise expression profile in patients with PDAC has
Figure 7. BAFF-R-overexpressing cell clones alter the expression of EMT-related genes. Four PDAC cell clones, which can overexpress
BAFF-R through transfection with a plasmid (pBCMGS-BAFF-R), were established. (A) In the four clones, overexpression of BAFF-R was confirmed, and
the proteins associated with EMT were found to be modulated in a BAFF-R level-dependent manner. (B) mRNA levels of each gene were evaluated
with real-time RT-PCR. Data are shown as means 6 SE of four separate experiments (*p,0.05, **p,0.01 vs. PANC-1). (C) The wound healing/scratch
test indicated that the motility of these cell clones was enhanced compared to the original PANC-1. (D) The percent wounded area filled of each clone
in the wound healing/scratch test is shown as a graph. Data are shown as means 6 SE of six separate experiments (*p,0.05, **p,0.01 vs. PANC-1).
doi:10.1371/journal.pone.0071367.g007
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not been previously defined. Recently, Nakajima et al. showed
through immunohistochemistry that BAFF-expressing B lympho-
cytes infiltrate synovial tissues of rheumatoid arthritis [26]. The
majority of infiltrating cells in the tissue surrounding PDAC in the
present study were BAFF-expressing B lymphocytes. Moreover,
many of these B lymphocytes also expressed BAFF-R. From these
results, the infiltrating BAFF-expressing B lymphocytes could be
considered to have an important role in the upregulation of BAFF
in PDAC patients. The increased BAFF likely has a role in the
progression of PDAC, because serum levels of BAFF were
remarkably upregulated in the patients with advanced PDAC.
BAFF produced from these B lymphocytes may also have an
important role in the survival, activation, and proliferation of
infiltrating B lymphocytes surrounding PDAC.
BAFF belongs to the TNF superfamily, and is closely related to
APRIL. Both have an important role in the activation and
proliferation of B lymphocytes. BAFF binds to all three BAFF
receptors (BAFF-R, BCMA and TACI), whereas APRIL binds to
two of them (BCMA and TACI). In the present study, only serum
levels of BAFF (not APRIL) were significantly upregulated in
patients with PDAC, and only the expression of BAFF-R could be
detected in PDAC tissues. Thus, the role of BAFF and BAFF-R in
PDAC was further explored. One of the most important BAFF-
induced mechanisms is activation of NF-kB. It has been reported
that BAFF-R activates NF-kB-inducing kinase (NIK), and that
activation of NIK induces the processing of transcription factor
NF-kB2 p100 to NF-kB2 p52 [27,28]. The correlation between
the activation of NF-kB and expression of Snail has previously
been reported [29]. NF-kB appears to have an important role in
the induction of EMT.
EMT is the phenomenon in which epithelial cells convert to
mesenchymal cells; it is fundamental for embryonic development
and involves profound phenotypic changes including loss of cell-
cell adhesion and cell polarity and acquisition of migratory and
invasive properties [30]. In previous reports, EMT has been
characterized by the acquisition of a spindle-like/fibroblastic
morphology, upregulation of mesenchymal markers like vimentin,
and downregulation of epithelial marker like E-cadherin [31,32].
Snail has been considered to be a trigger of EMT through
downregulation of the expression of epithelial markers and
upregulation of the expression of mesenchymal markers [33].
These molecules were upregulated by BAFF in PDAC cells;
downregulation of E-cadherin and upregulation of vimentin were
also observed in these cells.
From the present results, it is proposed that BAFF and BAFF-R
signaling induces EMT in PDAC cells (Fig. 8). PDAC cells
modulated by increased BAFF show a spindle-shaped morphol-
ogy, lose cell-cell adhesion and cell polarity, and acquire the ability
of cell motility and invasion. It is widely accepted that E-cadherin
plays a critical role in EMT, an early event in cancer cell invasion
and metastasis [34]. EMT is considered to be an important event
during malignant tumor progression and metastasis [35,36].
Therefore, these findings raise the possibility that infiltration of
BAFF-expressing B lymphocytes increases the malignant potential
of PDAC. Increased BAFF in tissue surrounding PDAC may
provide a therapeutic target for controlling the progression of
PDAC. Recently, an anti-BAFF antibody (BelimumabH) has been
proposed for use in clinical studies against autoimmune diseases
like rheumatoid arthritis [37]. Moreover, the anti-CD20 antibody
(RituximabH) was established for clinical use in patients with
malignant B cell lymphoma and with autoimmune diseases such as
rheumatoid arthritis [38,39]. These drugs may also be effective in
patients with advanced PDAC; however, for clinical use, further
evaluation of their efficacy in animal models is needed.
In conclusion, it was found that serum levels of BAFF were
elevated in patients with PDAC, particularly in patients with
metastatic disease. BAFF-expressing B lymphocytes remarkably
infiltrated the tissues surrounding the PDAC. Secreted BAFF may
induce tumor progression and metastasis through modulation of
EMT-associated genes. In the future, BAFF may be of use in
clinical treatment designed to control the malignant potential of
PDAC.
Supporting Information
Figure S1 The levels of GAPDH mRNA were not altered
by the treatment of BAFF. The levels of GAPDH mRNA were
compared with the levels of b-actin mRNA over different doses of
BAFF. The relative expression levels were not altered by the
treatment of BAFF. Data are shown as means 6 SE of four
separate experiments.
(TIF)
Figure S2 FACS analysis for the PANC-1 cells and
human BAFF-R transfect cell clones with anti–BAFF-R
antibodies. PANC-1 cells and human BAFF-R transfect cell
clones were stained with anti-BAFF-R antibodies. The blue line
indicates the stained cells with anti-BAFF-R antibody, and the red
line indicates controls.
(TIF)
Figure S3 Functional signaling of transduced BAFF-R
occurred in the BAFF-R-overexpressing cell clones.
Expression of NF-kB p52 was increased by adding 200 ng/mL
of BAFF in each BAFF-R-overexpressing cell clone.
(TIF)
Table S1 Antibodies used.
(DOC)
Table S2 Primer sequences used for real-time PCR.
(DOC)
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